Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Brazil's former President Jair Bolsonaro seeks house arrest for prison time citing health issues - 2How the Iran war may affect your money and bills
- 3Shredded cheese recall: Multiple brands sold at Aldi, Target and Walmart affected over potential metal fragment contamination
- 4Oil rises above $115 and Asia stocks slide as Iran war escalates
- 512 Once-In-A-Lifetime Travel Experiences To Add to Your Bucket List
- Investigate Business Mastercard Choices for Better Rewards and Rewards
- Lucky airplane passengers capture NASA's Artemis 2 moon launch from the sky
- The Best 20 Tunes that Characterized an Age
- 10 Natural products to Remember for Your Eating routine for a Better You
- Russian military plane crashes in annexed Crimea, killing 29 people on board
- Hunger and makeshift shelters persist in north Caribbean nearly 2 months after Hurricane Melissa
- Favored Vehicle for Seniors: Make Your Determination
- 21 Incredibly Interesting Contemplations To Observe Consistently
- Extraordinary Shows to Long distance race on a Plane
